![Takuya Kaneko](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Takuya Kaneko
Corporate Officer/Principal chez
GNI GROUP LTD.
Profil
Takuya Kaneko started working at Cellusion Inc. in 2022 and holds the position of Chief Executive Officer since 2025.
In 2025, Mr. Kaneko also began working at GNI Group Ltd. as Chief Strategy Officer & Executive Officer.
Both positions are currently held.
Postes actifs de Takuya Kaneko
| Sociétés | Poste | Début |
|---|---|---|
| GNI GROUP LTD. | Corporate Officer/Principal | 01/08/2025 |
Cellusion Inc.
 Cellusion Inc. Miscellaneous Commercial ServicesCommercial Services Engages in regenerating corneal endothelium using IPS cells for treatment of bullous keratopathy | Directeur Général | 01/02/2025 |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
6
Relations au 1er degré
2
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
GNI Group Ltd.
 GNI Group Ltd. BiotechnologyHealth Technology Engages in research and development, manufacture and sale of pharmaceutical products | Health Technology |
Cellusion Inc.
Cellusion Inc. Miscellaneous Commercial ServicesCommercial Services Engages in regenerating corneal endothelium using IPS cells for treatment of bullous keratopathy | Commercial Services |
